However, the association between different ICIs and pancreatitis remains controversial, as some other studies have demonstrated that both anti-CTLA4 alone and combination treatments with nivolumab and ipilimumab are associated with a higher incidence of pancreatitis than anti-PD-1/PD-L1 alone (Su et al., 2018; George et al., 2019; Bai et al., 2021). The gene discussed is CTLA4; the disease is pancreatitis.